What is HEALTHLYNKED CORP's earnings per share (EPS)?

HEALTHLYNKED CORP (HLYK) reported diluted earnings per share of -$1.16 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

HEALTHLYNKED CORP (HLYK) Financials

HLYK

Trailing 12 months to June 30, 2026

Revenue $1.4M -46.7% YoY

Net Income -$4.0M +19.9% YoY

EPS (Diluted) -$1.38 YoY not available

Operating Cash Flow -$1.4M +45.4% YoY

Market Cap $6.7M as of Oct 7, 2026

Price / Sales 4.9x on $1.4M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HLYK SEC filings page.

HEALTHLYNKED CORP (HLYK) reported $1.4M in revenue over the twelve months to Jun 30, 2026, down 46.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HLYK FY2025 2026-10-03

The business is shrinking faster than it is repairing losses, with weak liquidity and financing supporting operations.

Scale has contracted sharply: revenue fell from $5.7M in FY2023 to $2.1M in FY2025, yet operating profitability remained deeply negative. The operating margin improved from -72.6% to -102.3%, indicating that lower sales have not been matched by enough cost reduction.

The balance sheet has moved into negative equity: FY2025 liabilities were $7.5M against $1.7M of assets. A 0.2 current ratio and negative equity of $5.8M indicate that short-term obligations substantially exceed current resources and the company is financed primarily through liabilities.

Operations are not self-funded by operating cash: FY2025 operating cash outflow was $1.7M while financing provided $1.5M. The reported liquidity comparison was just 0.3 months of the latest annual outflow, showing how dependent the reported position is on outside financing alongside continued operating support.

Financial Health Signals

Financial health score not available

HEALTHLYNKED CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-47.76

HEALTHLYNKED CORP scores -47.76, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6.7M) relative to total liabilities ($7.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

HEALTHLYNKED CORP passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

HEALTHLYNKED CORP reported a net loss of $3.3M while operations used $1.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$250K

YoY-57.8%

QoQ-41.0%

HEALTHLYNKED CORP generated $250K in revenue in Q2 2026. This represents a decrease of 57.8% from the same quarter a year earlier. Against the prior quarter it is down 41.0%.

EBITDA

-$529K

YoY-29.5%

QoQ+21.7%

HEALTHLYNKED CORP's EBITDA was -$529K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 29.5% from the same quarter a year earlier. Against the prior quarter it is up 21.7%.

Net Income

-$820K

YoY-16.9%

QoQ+49.4%

HEALTHLYNKED CORP reported -$820K in net income in Q2 2026. This represents a decrease of 16.9% from the same quarter a year earlier. Against the prior quarter it is up 49.4%.

EPS (Diluted)

-$0.28

QoQ+50.0%

HEALTHLYNKED CORP earned -$0.28 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 50.0%.

Cash & Balance Sheet

Cash & Debt

$13K

YoY-36.4%

QoQ-46.4%

5Y CAGR-65.4%

HEALTHLYNKED CORP held $13K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ+0.4%

5Y CAGR-58.2%

HEALTHLYNKED CORP had 3M shares outstanding in Q2 2026. Against the prior quarter it is up 0.4%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

None of these metrics is reported for Q2 2026.

HLYK Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HLYK quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	$1.4M	$2.1M-31.3%	$3.0M-47.4%	$5.7M-2.3%	$5.9M-9.8%	$6.5M+5.9%	$6.1M+52.6%	$4.0M+77.9%	$2.3M+7.4%	$2.1M	N/A
SG&A Expenses	$2.3M	$2.0M-33.0%	$3.0M-16.1%	$3.6M-20.8%	$4.6M-7.1%	$4.9M+60.9%	$3.1M+5.1%	$2.9M+2.5%	$2.8M+53.9%	$1.8M+19.8%	$1.5M
Operating Income	-$2.3M	-$2.1M+54.8%	-$4.7M-12.7%	-$4.2M+52.1%	-$8.7M-62.4%	-$5.3M-73.5%	-$3.1M+4.3%	-$3.2M-8.0%	-$3.0M-65.9%	-$1.8M-52.5%	-$1.2M
EBITDA	N/A	-$2.0M+54.2%	-$4.4M-15.7%	-$3.8M+51.5%	-$7.8M-73.9%	-$4.5M-59.4%	-$2.8M+9.9%	-$3.1M-6.4%	-$2.9M-66.8%	-$1.8M-52.7%	-$1.2M
Interest Expense	N/A	N/A	N/A	$21K	$0	N/A	N/A	$244K+26.4%	$193K+93.8%	$100K+172.1%	$37K
Net Income	-$4.0M	-$3.3M+46.5%	-$6.1M-505.8%	-$1.0M+88.5%	-$8.8M+15.3%	-$10.4M-80.9%	-$5.8M-4.1%	-$5.5M+4.5%	-$5.8M-124.4%	-$2.6M-87.5%	-$1.4M
EPS (Basic)	N/A	-$1.16+46.8%	-$2.18	$0.00+100.0%	-$0.04+20.0%	-$0.05-25.0%	-$0.04+33.3%	-$0.06+14.3%	-$0.07-75.0%	-$0.04-100.0%	-$0.02
EPS (Diluted)	-$1.38	-$1.16	-$2.18	$0.00+100.0%	-$0.04+20.0%	-$0.05-25.0%	-$0.04	-$0.06+14.3%	-$0.07-75.0%	-$0.04-100.0%	-$0.02
Diluted Shares (Avg)	N/A	3M	3M-98.9%	263M+8.0%	243M+8.4%	225M+57.3%	143M	99M+25.7%	79M+13.3%	70M+15.9%	60M

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q
Revenue	$250K-57.8%	$423K-45.3%	$310K-49.9%	$389K-34.2%	$592K-25.5%	$774K-22.9%	$619K-33.5%	$590K-55.7%
SG&A Expenses	$517K+14.6%	$847K+34.6%	$454K-17.0%	$501K-20.7%	$452K-47.6%	$629K-37.0%	$546K-40.5%	$632K-17.7%
Operating Income	-$539K-23.7%	-$701K-13.5%	-$531K+29.1%	-$530K+68.3%	-$435K+59.7%	-$617K+47.6%	-$749K+32.7%	-$1.7M-41.1%
EBITDA	-$529K-29.5%	-$675K-14.5%	-$504K+30.0%	-$509K+67.9%	-$408K+58.9%	-$589K+46.0%	-$720K+29.6%	-$1.6M-44.8%
Interest Expense	$1K-98.1%	N/A	N/A	N/A	$73K	N/A	N/A	N/A
Net Income	-$820K-16.9%	-$1.6M-54.3%	-$676K+45.0%	-$852K+56.8%	-$701K+54.5%	-$1.1M+24.3%	-$1.2M+4.3%	-$2.0M-1028.0%
EPS (Basic)	-$0.28-12.0%	-$0.56-51.4%	-$0.24+45.5%	-$0.30+57.1%	-$0.25-2400.0%	-$0.37	-$0.44	-$0.70
EPS (Diluted)	-$0.28	-$0.56	-$0.24	-$0.30	-$0.25	-$0.37	-$0.44	-$0.70
Diluted Shares (Avg)	3M	3M	N/A	3M	3M	3M-99.0%	N/A	3M-98.9%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Income Tax.

HLYK Balance Sheet

HLYK quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$1.7M-23.4%	$2.2M-48.1%	$4.3M-6.6%	$4.6M-57.2%	$10.7M+33.2%	$8.0M+215.2%	$2.5M+495.9%	$427K-2.8%	$440K+33.5%	$330K
Current Assets	$1.6M-5.5%	$1.6M+150.1%	$656K-69.4%	$2.1M-41.3%	$3.7M+804.6%	$404K+0.2%	$403K+7.3%	$375K+2.3%	$367K+47.3%	$249K
Cash & Equivalents	$37K-51.3%	$76K-69.2%	$247K+299.4%	$62K-98.1%	$3.3M+1929.6%	$162K+46.9%	$110K-18.7%	$136K+171.5%	$50K-14.8%	$59K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$18K-59.8%	$45K-66.5%	$133K-30.9%	$193K+42.9%	$135K+41.7%	$95K+35.1%	$70K	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$21K-71.1%	$72K-16.2%	$86K-1.0%	$87K+4.7%	$83K-27.5%	$115K+1.4%	$113K-22.8%	$147K
Long-Term Investments	$0	$0	$0	$0-100.0%	$1.5M	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	$320K-58.2%	$766K-33.3%	$1.1M+1497.6%	$72K	N/A	N/A	N/A
Total Liabilities	$7.5M+39.5%	$5.4M+54.0%	$3.5M-18.5%	$4.3M+22.2%	$3.5M-47.7%	$6.7M+23.9%	$5.4M+60.3%	$3.4M+35.0%	$2.5M+100.7%	$1.2M
Current Liabilities	$7.0M+49.5%	$4.7M+94.4%	$2.4M-30.6%	$3.5M+81.2%	$1.9M-60.7%	$4.9M-0.5%	$4.9M+46.1%	$3.4M+36.0%	$2.5M+156.1%	$964K
Non-Current Liabilities	$451K-31.9%	$662K-37.7%	$1.1M+34.3%	$792K-49.7%	$1.6M-12.4%	$1.8M+273.5%	$481K+15613.2%	$3K-85.7%	$21K-92.3%	$277K
Long-Term Debt	N/A	N/A	N/A	$45K-55.6%	$101K+464.3%	$18K	N/A	$3K-85.7%	$21K-46.2%	$40K
Total Equity	-$5.8M-84.1%	-$3.1M-488.9%	$805K+155.9%	$314K-95.6%	$7.2M+433.6%	$1.4M+147.5%	-$2.8M+3.1%	-$2.9M-43.1%	-$2.1M-125.0%	-$912K
Retained Earnings	-$50.5M-4.9%	-$48.2M-14.6%	-$42.0M-2.5%	-$41.0M-27.4%	-$32.2M-47.8%	-$21.8M-35.9%	-$16.0M-52.6%	-$10.5M-123.2%	-$4.7M-121.5%	-$2.1M

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q
Total Assets	$1.6M-13.8%	$1.6M-21.0%	$1.7M-23.4%	$1.8M-36.0%	$1.8M-52.1%	$2.1M-47.1%	$2.2M-48.1%	$2.8M-51.5%
Current Assets	$1.5M-0.9%	$1.5M-1.8%	$1.6M-5.5%	$1.5M-15.4%	$1.6M-22.3%	$1.6M-17.3%	$1.6M+150.1%	$1.8M-17.1%
Cash & Equivalents	$13K-36.4%	$24K+7.6%	$37K-51.3%	$11K-27.1%	$20K-88.3%	$22K-5.2%	$76K-69.2%	$15K-70.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$18K-33.7%	$18K-42.7%	$18K-59.8%	$32K-59.4%	$28K-71.4%	$32K-76.3%	$45K-66.5%	$79K-44.6%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$26K-38.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$9.3M+41.6%	$8.6M+39.6%	$7.5M+39.5%	$7.2M+53.4%	$6.6M+54.1%	$6.2M+68.8%	$5.4M+54.0%	$4.7M+13.6%
Current Liabilities	$8.9M+45.2%	$8.2M+46.4%	$7.0M+49.5%	$6.7M+77.2%	$6.1M+80.4%	$5.6M+107.8%	$4.7M+94.4%	$3.8M+13.3%
Non-Current Liabilities	$450K-5.2%	$450K-24.4%	$451K-31.9%	$454K-48.7%	$475K-46.6%	$595K-38.9%	$662K-37.7%	$884K+15.2%
Total Equity	-$7.8M-63.1%	-$7.0M-69.7%	-$5.8M-84.1%	-$5.4M-181.1%	-$4.8M-1019.3%	-$4.1M-1967.9%	-$3.1M-488.9%	-$1.9M-223.8%
Retained Earnings	-$53.0M-6.2%	-$52.2M-6.1%	-$50.5M-4.9%	-$50.8M-8.2%	-$49.9M-11.0%	-$49.2M-13.3%	-$48.2M-14.6%	-$46.9M-15.2%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

HLYK Cash Flow Statement

HLYK quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$1.4M	-$1.7M+51.0%	-$3.5M+15.7%	-$4.1M+5.0%	-$4.4M-15.7%	-$3.8M-78.1%	-$2.1M+10.4%	-$2.4M-0.3%	-$2.4M-45.5%	-$1.6M-114.1%	-$756K
Depreciation & Amortization	N/A	$102K-64.0%	$283K-19.6%	$352K-57.6%	$829K+0.2%	$828K+234.6%	$247K+237.1%	$73K+208.6%	$24K+0.7%	$24K+43.4%	$16K
Stock-Based Compensation	N/A	$159K-24.6%	$210K-30.8%	$304K+204.0%	$100K	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	$3K+73.2%	$2K-93.6%	$24K+22.4%	$19K-23.0%	$25K+148.6%	$10K+235.0%	$3K-81.4%	$16K+28.0%	$13K
Free Cash Flow	N/A	N/A	-$3.5M+15.7%	-$4.1M+5.5%	-$4.4M-15.8%	-$3.8M-76.9%	-$2.1M+9.7%	-$2.4M-0.6%	-$2.4M-44.3%	-$1.6M-112.7%	-$769K
Investing Cash Flow	N/A	$125K-70.4%	$422K-88.0%	$3.5M+743.6%	-$545K-59.6%	-$341K-118.8%	$1.8M+481.5%	-$475K-15724.7%	-$3K+81.4%	-$16K-28.0%	-$13K
Financing Cash Flow	$1.3M	$1.5M-46.6%	$2.9M+252.0%	$824K-50.9%	$1.7M-76.8%	$7.2M+1929.3%	$357K-87.3%	$2.8M+15.0%	$2.4M+50.3%	$1.6M+103.9%	$798K
Dividends Paid	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$8K	N/A	$1K	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$350K+16.1%	-$222K+48.7%	-$419K+43.6%	-$444K+57.2%	-$418K+51.4%	-$433K+49.4%	-$744K+37.6%	-$1.0M+17.0%
Depreciation & Amortization	$10K-62.4%	$26K-7.1%	$26K-7.0%	$20K-75.6%	$27K-68.1%	$28K-67.6%	$28K-67.8%	$83K-5.3%
Stock-Based Compensation	N/A	$298K+4075.2%	N/A	$5K+2294.9%	N/A	$7K-92.3%	N/A	$196
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$744K+37.6%	-$1.0M
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$425K-64.2%	$0-100.0%
Financing Cash Flow	$339K-18.4%	$209K-44.8%	$321K-15.6%	$435K-50.5%	$415K-58.8%	$379K-40.3%	$380K+88.1%	$879K+3693.9%
Dividends Paid	$0	$36K	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Share Buybacks.

HLYK Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HLYK quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Margin	-102.3%	-155.5%	-72.5%	-147.8%	-82.0%-32.0pp	-50.1%+29.8pp	-79.8%	-131.6%	-85.2%	N/A
Net Margin	-158.8%	-203.8%	-17.7%	-150.5%	-160.3%	-93.8%	-137.6%	-256.3%	-122.7%	N/A
Return on Equity	N/A	N/A	-125.8%+2677.8pp	-2803.5%-2659.0pp	-144.5%+281.8pp	-426.3%	N/A	N/A	N/A	N/A
Return on Assets	-192.7%+83.1pp	-275.8%-252.2pp	-23.6%+168.8pp	-192.5%-95.1pp	-97.4%-25.7pp	-71.7%+145.4pp	-217.1%+1137.9pp	-1355.0%-768.1pp	-586.9%-169.2pp	-417.7%
Current Ratio	0.22-0.1x	0.35+0.1x	0.27-0.3x	0.62-1.3x	1.90+1.8x	0.080.0x	0.080.0x	0.110.0x	0.15-0.1x	0.26
Debt-to-Equity	N/A	N/A	4.32+4.2x	0.14+0.1x	0.010.0x	0.01	N/A	N/A	N/A	N/A
Asset Turnover	1.21-0.1x	1.350.0x	1.34+0.1x	1.28+0.7x	0.61-0.2x	0.76-0.8x	1.58-3.7x	5.29+0.5x	4.78	N/A
FCF Margin	N/A	-116.2%	-72.5%+2.4pp	-74.9%-16.6pp	-58.3%-23.4pp	-34.9%+24.1pp	-59.0%	-104.4%	-77.7%	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q
Operating Margin	-215.7%	-165.5%	-171.2%	-136.3%	-73.5%	-79.7%	-121.0%	-283.2%
Net Margin	-328.1%	-382.9%	-218.1%	-219.2%	-118.3%	-135.7%	-198.8%	-334.4%
Return on Assets	-51.5%-13.5pp	-99.7%-48.6pp	-39.7%+15.6pp	-48.3%+23.3pp	-37.9%+2.0pp	-51.1%-15.4pp	-55.3%-25.3pp	-71.5%-68.5pp
Current Ratio	0.17-0.1x	0.19-0.1x	0.22-0.1x	0.23-0.3x	0.25-0.3x	0.28-0.4x	0.35+0.1x	0.48-0.2x
Asset Turnover	0.16-0.2x	0.26-0.1x	0.18-0.1x	0.220.0x	0.32+0.1x	0.38+0.1x	0.28+0.1x	0.210.0x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-120.1%	-175.7%

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$5.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
HEALTHLYNKED CORP HLYK	FY2025	$2.1M	-$3.3M	N/A	$6.7M	—
SELECTIS HEALTH INC GBCS	FY2025	$41.4M	-$1.0M	-2.5%	$17.6M	—
BIOCORRX INC NEW BICX	FY2025	$797K	-$3.4M	N/A	$6.0M	—

Where HEALTHLYNKED CORP Ranks

Frequently Asked Questions

What is HEALTHLYNKED CORP's annual revenue?

HEALTHLYNKED CORP (HLYK) reported $2.1M in total revenue for fiscal year 2025. This represents a -31.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is HEALTHLYNKED CORP's revenue growing?

HEALTHLYNKED CORP (HLYK) revenue declined by 31.3% year-over-year, from $3.0M to $2.1M in fiscal year 2025.

Is HEALTHLYNKED CORP profitable?

No, HEALTHLYNKED CORP (HLYK) reported a net income of -$3.3M in fiscal year 2025.

What is HEALTHLYNKED CORP's EBITDA?

HEALTHLYNKED CORP (HLYK) had EBITDA of -$2.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is HEALTHLYNKED CORP's operating cash flow?

HEALTHLYNKED CORP (HLYK) recorded an outflow of $1.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are HEALTHLYNKED CORP's total assets?

HEALTHLYNKED CORP (HLYK) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does HEALTHLYNKED CORP have outstanding?

HEALTHLYNKED CORP (HLYK) had 3M shares outstanding as of fiscal year 2025.

What is HEALTHLYNKED CORP's current ratio?

HEALTHLYNKED CORP (HLYK) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is HEALTHLYNKED CORP's return on assets (ROA)?

HEALTHLYNKED CORP (HLYK) had a return on assets of -192.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is HEALTHLYNKED CORP's P/E ratio?

HEALTHLYNKED CORP (HLYK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $6.7M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is HEALTHLYNKED CORP's price-to-sales ratio?

HEALTHLYNKED CORP (HLYK) trades at 4.9x sales, its market capitalization divided by revenue of $1.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $6.7M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does HEALTHLYNKED CORP's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, HEALTHLYNKED CORP (HLYK) held $37K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.7M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is HEALTHLYNKED CORP's debt-to-equity ratio negative or not reported?

HEALTHLYNKED CORP (HLYK) has negative shareholder equity of -$5.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is HEALTHLYNKED CORP's Altman Z-Score?

HEALTHLYNKED CORP (HLYK) has an Altman Z-Score of -47.76, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is HEALTHLYNKED CORP's Piotroski F-Score?

HEALTHLYNKED CORP (HLYK) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are HEALTHLYNKED CORP's earnings high quality?

HEALTHLYNKED CORP (HLYK) reported a net loss of $3.3M while operations used $1.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.